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The role of the PI 3-Kinase isoform p110 for vascular remodeling in 
experimental pulmonary hypertension 
 
Pulmonary arterial hypertension (PAH) is a devastating vascular disease 
characterized by chronically elevated pulmonary artery pressure (PAP) and 
pulmonary vascular resistance (PVR), which is mainly due to vascular remodeling 
processes occurring in pulmonary arterioles. Pulmonary arterial smooth muscle cells 
(PASMCs) are crucially involved in these processes as they display an increased 
proliferation and migration, mainly triggered by peptide growth factors. Previous work 
demonstrated that PI 3-kinase (PI3K) is a central mediator of SMC proliferation and 
migration.  
The main aims of this thesis were (i) to systematically characterize the importance of 
the catalytic class IA PI3K isoforms (p110, p110, p110) – which signal 
downstream of receptor tyrosine kinases – for cellular responses in human PASMCs, 
and (ii) to characterize the role of the identified isoform for the pathobiology of PH in 
vivo by utilizing a genetic and a pharmacological approach. 
In lung samples from PAH patients and from hypoxia-exposed mice, phosphorylation 
of the PI3K target AKT was profoundly increased as compared to healthy 
subjects/control mice, suggesting enhanced signaling via PI3K in these disease 
conditions. Using isoform-specific PI3K inhibitors, the catalytic subunit p110 was 
identified as the central downstream mediator of growth factor-induced proliferation 
and migration of human PASMCs. Based on these findings, a genetic mouse model 
was generated, harboring a targeted deletion of p110 in SMCs. Using this genetic 
model, it was demonstrated that lack of p110in SMCs blunts PASMC proliferation 
and migration induced by numerous growth factors that all contribute to disease 
progression SM-specific ablation of p110 and pharmacological inhibition using the 
p110 specific inhibitor PIK75 prevented vascular remodeling in the hypoxia-induced 
mouse model in vivo. The increase in the fraction of fully muscularized small 
pulmonary vessels by hypoxia and the decrease in the fraction of non-muscularized 
vessels were both normalized to nearly normoxia levels. Additionally, hypoxia-
induced medial wall thickening of the small vessels, elevation of right ventricular 
systolic pressure (RVPsys as a measure of PAP), determined by invasive 
hemodynamic measurement, and RV hypertrophy were prevented in both 
approaches. Furthermore, it was demonstrated that pharmacological inhibition of 
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p110 activity was able to profoundly reduce medial wall thickness and the degree of 
muscularization in a second model, monocrotaline-induced PH in the rat, even when 
the disease was fully established before treatment was initiated. This was associated 
with a significant reduction of the elevated RVPsys and partial reversal of RV 
hypertrophy in this model.  
These results reveal  
signaling prevent and reverse vascular remodeling and experimental PH, indicating 
an important role of p110 in the pathobiology of experimental PH. Therefore, 
inhibition of p110 represents a promising strategy for the treatment of PAH. 
 
 
